Evotec has bought University of Modena and Reggio Emilia spinout Rigenerand for $24.7m.

Rigenerand, an Italy-based cell technology spinout of University of Modena and Reggio Emilia, agreed to an acquisition by life sciences company Evotec yesterday for €23m ($24.7m). Rigenerand operates a current good manufacturing practice facility that specialises in complex cell-based therapies. Although Evotec does not expect to see a large financial impact from the acquisition in…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.